Market Overview

Roth Capital Initiates Spark Therapeutics At Buy

Share:

Analysts at Roth Capital initiated coverage on Spark Therapeutics, Inc. (NASDAQ: ONCE) with a Buy rating.

The target price for Spark Therapeutics is set to $71.

Spark Therapeutics' shares rose 0.87% to $46.40 in after-hours trading.

Latest Ratings for ONCE

DateFirmActionFromTo
Mar 2019BarclaysDowngradesOverweightEqual-Weight
Feb 2019Stifel NicolausDowngradesBuyHold
Feb 2019BernsteinDowngradesOutperformMarket Perform

View More Analyst Ratings for ONCE
View the Latest Analyst Ratings

 

Related Articles (ONCE)

View Comments and Join the Discussion!

Posted-In: Roth CapitalInitiation Analyst Ratings

Latest Ratings

StockFirmActionPT
URIVertical ResearchInitiates Coverage On310.0
PCARVertical ResearchInitiates Coverage On95.0
DEVertical ResearchInitiates Coverage On345.0
CNHIVertical ResearchInitiates Coverage On16.0
AGCOVertical ResearchInitiates Coverage On119.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com